zadnja posodobitev :
19/11/2024
Infostab
Seznami
Seznami
Poiščite združljivosti
Tabela združljivosti Y-strani
Viri
raziskovalne skupine
valistab
poster
Povezave
sponzorji
Avtor
Navodilo za uporabo
Newsletter
raziskovalne skupine - Quality Evaluation Team, Samsung Bioepis Co
Quality Evaluation Team, Samsung Bioepis Co
Incheon
sujin8171.park@samsung.com
Viri
(4)
1
In‑Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period.
Tak M, Jeong H, Yun J, Kim J, Kim S, Lee Y, Park S-J. (sujin8171.park@samsung.com)
Drugs R D -
2023
- ;23,4:363 - 375
2
Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
Park D, Kim J, Yun J, Park S.J. (sujin8171.park@samsung.com)
Adv Ther -
2020
- ; 37: 4308–4324.
3
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Yun J, Kim J, Chung J, Hwang S-J, Park S-J. (sujin8171.park@samsung.com)
Adv Ther -
2019
-
4
Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature.
Park D, Yun J, Hwang S-J, Park SJ. (sujin8171.park@samsung.com)
Adv Ther -
2019
- 36:442–450
molekule študiral
(4)
Adalimumab
Bevacizumab
Eculizumab
Trastuzumab
Mentions Légales